Issue: October 2018
October 11, 2018
1 min read
Save
This article is more than 5 years old. Information may no longer be current.
Trial Scorecard: FREED
Issue: October 2018
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Researchers evaluated febuxostat (Uloric, Takeda) to prevent cerebral and cardiorenovascular events in elderly patients with hyperuricemia at risk for cerebral and cardiorenovascular disease.